Tropomyosin 3 pseudogene 9 (TPM3P9)

Tropomyosin 3 pseudogene 9 (TPM3P9) is a pseudogene-derived lncRNA located on chromosome 19 that encodes a previously unrecognized microprotein of 92 amino acids. This microprotein, translated from the lncRNA TPM3P9, exhibits oncogenic activity in clear cell renal cell carcinoma (ccRCC). Mechanistically, TPM3P9 binds to the RRM1 domain of the splicing factor RBM4, thereby inhibiting RBM4-mediated exon skipping in the transcription factor TCF7L2. This leads to increased production of an oncogenic splice variant, TCF7L2-L, which in turn activates NF-κB signaling and promotes RELB expression, supporting tumor growth and cell proliferation. High TPM3P9 expression in tumors is correlated with worse clinical outcomes, including shorter overall and relapse-free survival in ccRCC. The protein is found in both the cytoplasm and nucleus. There is currently no evidence that TPM3P9 is a direct therapeutic target (such as a druggable receptor or enzyme), nor are there any approved drugs acting on it. Key clarifications: - Is target: TPM3P9 is not currently considered a classic therapeutic target (such as a receptor or enzyme), but its newly identified role suggests potential as a prognostic biomarker and possibly a future therapeutic candidate. - Is incorrect: The entry is potentially misleading as a therapeutic "target" since TPM3P9 is not an established class of classic drug targets, but could be important for future biomarker or experimental drug development. - Aliases and alternate names: TPM3P9, lncRNA-TPM3P9, tropomyosin 3 pseudogene 9. - Drug interactions/mechanisms/biomarkers: No known drugs or direct clinical interventions act on TPM3P9, but its expression serves as a marker for prognosis in ccRCC.

Other names

TPM3P9lncRNA-TPM3P9tropomyosin 3 pseudogene 9